Ocuphire Pharma Results Presentation Deck
25
APX3330 Product Candidate Profile for Multiple Retinal Indications
Oral, First-In-Class Ref-1 Inhibitor with Favorable Human Safety Data from 12 Completed Trials
APX3330: Well-tolerated Oral Dose up to 600 mg/day | Twice Daily Dosing
Favorable Safety Profile
Over 350 Subjects (Healthy, Liver, Cancer, Diabetic) Treated
Notably, Several Subjects Dosed ~1 Yr and Others 24-Wks
MOA and Efficacy Signals in DR
Novel MOA for Treating Retina
ā Inflammation
ā Abnormal Angiogenesis
Daily vs. episodic exposure
Good Patient Compliance in ZETA-1 with
Convenient Oral Dosing
APX3330 Demonstrated Slowing of
Progression of Diabetic Retinopathy
Few Systemic AEs Across All Doses (120mg-720mg)
< 5% Mild Skin Rash (reversible)
< 5% Mild Diarrhea
No Treatment-Related Organ Toxicity
(Liver, Cardiovascular {BP, HR}, Kidney, Neurologic, Pulmonary)
Minimal Ocular Side Effects*
Source: ZETA-1 Clinical Trial; *1 subject had vision blur thought to be related by investigator in ZETA-1
OcuphireView entire presentation